News

The AACI CAR T Initiative began in 2018 as a working group to discuss payment, reimbursement strategies, and patient access to U.S. Food and Drug Administration (FDA)-approved commercial chimeric antigen receptor T-cell (CAR T) therapies.

Recognizing the evolution of immunotherapies over the past several years, the AACI CAR T Steering Committee recently voted to change the name of the CAR T Initiative to AACI Cellular Therapy Initiative. Along with the new name, the steering committee will expand to include experts in other cellular-based therapies.

AACI Cellular Therapy Steering Committee Chair Peter Riedell, MD, said, "Since 2018, we have seen rapid growth in the field with now several CAR T treatments approved for hematologic malignancies. Recently, cellular therapy has moved into the solid tumor space with the approval of tumor infiltrating lymphocyte (TIL) therapy, and our name change reflects this natural growth and expansion of cellular therapeutics."

AACI is looking forward to continuing to support the cellular therapy community with the expanded initiative.